PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Summary

This is a Phase I, open label study aimed at assessing the pharmacokinetics, pharmacodynamics, the efficacy, safety, and tolerability of a single injection of XM22 in children with Ewing family of tumors or rhabdomyosarcoma scheduled to receive chemotherapy (CTX)

Timeline

Start

2012-07

Primary completion

2014-06

Completion

2015-04

Drugs

Indications